Twice this fall, I watched the same filing event happen in opposite directions. On August 20, QNB Corp moved from OTCQX to Nasdaq — a bank that had been a reporting company for years, with a real disclosure history, simply changing exchanges. A month later, Amaero Inc. showed up on Nasdaq with no US trading history at all, having spent its life to that point listed on the ASX under a different name. Both filed the same form, an 8-A12B, within weeks of each other. Both now owe the same thing: a first proxy that gets read harder than any proxy they will file again for years.
That is not an exaggeration of how ISS and Glass Lewis treat newly listed companies. It is the mechanical result of how the review actually works.
A proxy advisor scoring an established Nasdaq filer has five years of pay-versus-performance history to triangulate against. A newly listed company has none. There is no track record to say the committee has historically kept pay disciplined, no multi-year trend to smooth out one unusual year, no precedent for how this particular board behaves under pressure. The first proxy is read in isolation, which means every choice in it — the peer group, the mix of cash and equity, the rationale for whatever the outgoing private or OTC-era arrangement was — has to stand on its own.
And there are two distinct versions of this problem, not one.
The uplisting case has a paper trail, just not the right kind. QNB Corp was an SEC reporting company before the move, which means its historical officer compensation is a matter of public record — disclosed under the much lighter scrutiny that comes with being a small OTC-traded bank, where few institutional holders were reading closely and no proxy advisor was scoring the committee’s work. The compensation structure that existed on OTCQX does not disappear when the ticker moves to Nasdaq. It becomes the opening exhibit in a review it was never built for.
The fresh-IPO case has no paper trail at all, and that absence is its own problem. Amaero’s compensation decisions up to this point were made as a foreign private company reporting under ASX rules, where US-style peer benchmarking and say-on-pay exposure simply don’t apply. Electra Therapeutics, which priced its own IPO in the same September window, has the more familiar version of this: a pre-IPO package set by a venture board optimizing for retention and dilution, not for how it will read next to a Russell Microcap peer set. Neither company’s existing numbers were chosen with an eye toward the audience that will be scoring them within the year.
The market-cap spread in this one month of filings is worth sitting with, because it shows how differently “first proxy” can land depending on scale. Amaero’s listing computes to roughly $221 million — about 31.3 million shares at $7.06. Orion180 Insurance Group, which priced the same week, comes in around $1.19 billion on a fully diluted basis, large enough that its first proxy will draw the kind of institutional attention a $221 million company simply won’t get yet. The compensation discipline expected of each is not the same, but both are being asked for it starting now, not in three years once the market has gotten used to them.
Here is the part that should change how a committee thinks about timing, rather than just acknowledging the problem exists.
Every other trigger I write about here — a new CEO, a new CFO, a say-on-pay vote that came in under 70% — involves a number that already exists and now needs defending. The committee is reconstructing a rationale after the fact, which is always the harder version of the exercise. An uplisting or an IPO is the one case where that is not true yet. The number from the OTC era or the private-company era is already set, but the first public-company proxy’s framing of it is not. There is still time to build the peer group, decide what the disclosure narrative is, and have the benchmarking ready before a draft goes to outside counsel — rather than bolting a peer rationale onto a number after an advisor has already flagged it.
That is a different sequencing problem than the one most of this list faces, and it is a better one to have. Nobody is asking the committee to justify a decision it already made under scrutiny it didn’t anticipate. They are asking it to describe, clearly and with real comparables, a decision that was reasonable under the rules that applied at the time. That is a much easier story to tell — if it is told with an actual peer set, rather than reconstructed as a defensive afterthought once the advisor’s report comes back with the first pass-fail judgment the company has ever received.
The five mistakes that draw an “against” recommendation on peer group choice apply here exactly as they do anywhere else — the comparables have to be real, screened, and documented, not asserted. The difference for a newly listed company is only that there is no earlier proxy’s peer group to inherit or correct. The first one is the one that sets precedent for every proxy after it. Worth getting right before anyone else reads it first.